公开(公告)号：US20240336690A1

公开(公告)日：2024-10-10

申请号：US18293425

申请日：2022-08-01

申请人： SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

发明人： JUN HO CHUNG ,  KYUNG HO CHOI ,  SANG IL KIM ,  YOUNG JAE LEE ,  SU JEONG KIM ,  SEO RYEONG PARK ,  SI WON HWANG ,  DONG MIN KANG ,  SU REE KIM

IPC分类号： C07K16/28 ,  A61K47/68

CPC分类号： C07K16/2875 ,  A61K47/6803 ,  A61K47/68031 ,  A61K47/6849 ,  C07K2317/622 ,  C07K2317/76

摘要： An antibody binds to CD154. The antibody includes HCDR, which includes amino acid sequences of SEQ ID NOs: 1 to 3, and LCDR which includes amino acid sequences of SEQ ID NOs: 4 to 6. A composition including an antibody-drug conjugate in which a drug is conjugated to the antibody may prevent or treat a T cell-mediated autoimmune disease and/or organ transplant rejection.

公开(公告)号：US20240316209A1

公开(公告)日：2024-09-26

申请号：US18044943

申请日：2021-09-10

申请人： BrickBio, Inc.

发明人： James Sebastian Italia ,  Nikolaos Biris

IPC分类号： A61K47/68 ,  C07K16/32 ,  C12N9/00

CPC分类号： A61K47/68031 ,  A61K47/6889 ,  C07K16/32 ,  C12N9/93 ,  C12Y601/01001 ,  C12Y601/01026

摘要： The invention relates generally to engineered antibodies containing unnatural amino acids (UAAs) and methods of making and using such antibodies.

公开(公告)号：US20240293565A1

公开(公告)日：2024-09-05

申请号：US18570403

申请日：2022-06-15

申请人： BEIJING SINOTAU BIO-PHARMACEUTICALS TECHNOLOGY CO., LTD.

发明人： Xiaoyan ZHONG ,  Zhe Li ,  Jie ZHU

IPC分类号： A61K47/68 ,  A61K35/00 ,  C07K16/32

CPC分类号： A61K47/68031 ,  A61K35/00 ,  A61K47/6849 ,  A61K47/6889 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

摘要： Provided is an anti-HER3 antibody, or an antibody drug conjugate (ADC) containing the anti-HER3 antibody. Also provided is the use of the antibody or ADC in the treatment of HER3-expression cancers.

公开(公告)号：US20240277865A1

公开(公告)日：2024-08-22

申请号：US18567765

申请日：2022-06-08

申请人： Academia Sinica

发明人： An-Suei YANG ,  Hung-Ju HSU ,  Chao-Ping TUNG ,  Chung-Ming YU ,  Chi-Yung CHEN ,  Hong-Sen CHEN ,  Yu-Chuan HUANG ,  Pei-Hsun TSAI ,  Szu-Yu LIN ,  Hung-Pin PENG

IPC分类号： A61K47/68 ,  A61K39/00 ,  A61P35/00 ,  C07K16/00 ,  C07K16/30

CPC分类号： A61K47/6851 ,  A61K47/68031 ,  A61K47/6829 ,  A61P35/00 ,  C07K16/005 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73

摘要： Disclosed herein is a phage-displayed single-chain variable fragment (scFv) library, which comprises a plurality of phage-displayed scFvs characterized with a specific sequence in each CDR. The present phage-displayed scFv library is useful in selecting an antibody fragment exhibiting a binding affinity and specificity to mesothelin (MSLN). Also disclosed herein are a recombinant antibody specific to MSLN, an immunoconjugate comprising the recombinant antibody, and uses thereof in treating cancers.

公开(公告)号：US20240238433A1

公开(公告)日：2024-07-18

申请号：US18562788

申请日：2022-05-20

申请人： Agency for Science, Technology and Research

发明人： Boon Hwa Andre CHOO ,  Ting Hwee GOH ,  Mei Yee DING ,  Hau Wan LEUNG ,  Simone DORFMUELLER ,  Ban Xiong TAN ,  Chek Shik LIM ,  Walter STUNKEL

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574 ,  G01N33/58

CPC分类号： A61K47/68031 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/2803 ,  G01N33/57492 ,  G01N33/58 ,  C07K2317/565 ,  C07K2317/567

摘要： The invention relates to anti-CEACAM5/6 antigen-binding molecules and humanized variants thereof that bind to CEACAM5/6 that is glycosylated at N256. It also relates to the use of said antigen-binding molecules in methods of detection and medical treatment thereof.

公开(公告)号：US20240238431A1

公开(公告)日：2024-07-18

申请号：US18288258

申请日：2022-04-26

申请人： XUANZHU BIOPHARMACEUTICAL CO., LTD. ,  BEIJING XUANZHU COMBIO CO., LTD.

发明人： Xiaodong ZHU ,  Jintong YE ,  Jinfeng WANG ,  Wei HE

IPC分类号： A61K47/68 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32

CPC分类号： A61K47/68031 ,  A61K45/06 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  C07K16/32

摘要： The present invention relates to a bispecific antibody-drug conjugate comprising a bispecific antibody, a toxin, and a linker, and to a pharmaceutical composition comprising the bispecific antibody-drug conjugate, and a use of the bispecific antibody-drug conjugate and the pharmaceutical composition thereof in the preparation of medicaments for preventing and/or treating cancer. The bispecific antibody comprises a first paratope capable of recognizing and/or binding to domain II of HER2, and a second paratope capable of recognizing and/or binding to domain IV of HER2; the toxin is selected from the group consisting of maytansines, hemiasterlins, amanitins, auristatins, calicheamicins and duocarmycins; the linker is a cleavable linker or a non-cleavable linker; alternatively, one or more hydrogen atoms in the toxin and/or linker are optionally deuterated.

公开(公告)号：US20240226319A1

公开(公告)日：2024-07-11

申请号：US18561506

申请日：2022-05-23

申请人： MERCK PATENT GMBH

发明人： Sebastian JAEGER ,  Christian SCHROETER

IPC分类号： A61K47/68 ,  A61K49/00 ,  A61P35/00

CPC分类号： A61K47/6849 ,  A61K47/68031 ,  A61K49/0002 ,  A61P35/00

摘要： The invention relates to EGFR targeting Fc antigen binding fragment-drug conjugates (EGFR Fcab-drug conjugates) and the use of the EGFR Fcab-drug conjugates of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such EGFR Fcab-drug conjugates. Further, the invention relates to EGFR Fcab-label conjugates and diagnostic compositions containing such EGFR Fcab-label conjugates.

公开(公告)号：US20240207425A1

公开(公告)日：2024-06-27

申请号：US18536350

申请日：2023-12-12

申请人： Merck Sharp & Dohme LLC

发明人： Manoj B. Charati ,  John A. Flygare ,  Rebecca Elizabeth Johnson ,  Simon B. Lang ,  W. Michael Seganish

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12

CPC分类号： A61K47/68031 ,  A61P35/00 ,  C07D401/12 ,  C07D403/12

摘要： The present disclosure is directed to linker-payloads, and pharmaceutically acceptable salts, solvates, or stereoisomer thereof, comprising a structure of formula I:




The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds, intermediates thereof, and compositions in the prevention or treatment of cancers and/or tumors.

公开(公告)号：US20240166759A1

公开(公告)日：2024-05-23

申请号：US18473511

申请日：2023-09-25

申请人： Angiex, Inc.

发明人： Paul A. Jaminet ,  Shou-Ching S. Jaminet ,  Gabriel Gonzalez

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61K47/68031 ,  A61K47/68033 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/507 ,  C07K2317/565

摘要： Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described and antibody drug conjugates containing the same, and combinations of such antibodies and ADCs with an immunotherapy, such as an immunomodulatory agent.

公开(公告)号：US20240132595A1

公开(公告)日：2024-04-25

申请号：US18275519

申请日：2022-01-28

申请人： Agency for Science, Technology and Research

发明人： Chui Ping Angela CHIN ,  Boon Hwa Andre CHOO ,  Wey Jia FONG ,  Mei Yee Vanessa DING

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC分类号： C07K16/2833 ,  A61K47/68031 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/565

摘要： The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.